Presentation at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting Highlights Ashvattha Product Candidates for Neuroinflammation Imaging and Treatment
Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the